Procarbazine in haematology: An old drug with a new life?

European Journal of Cancer

Volumn 40, Issue 13, 2004, Pages 1924-1927

  Massoud, M ^a   Armand, J P ^a   Ribrag, V ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

Chemotherapy; Drug resistance; Lymphoid malignancies; Procarbazine

Indexed keywords

ADRENERGIC RECEPTOR STIMULATING AGENT; ANTIDEPRESSANT AGENT; BLEOMYCIN; CHLORMETHINE; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; PREDNISOLONE; PROCARBAZINE; TYRAMINE; VINCRISTINE; YOGHURT;

ANTINEOPLASTIC ACTIVITY; BANANA; CANCER CHEMOTHERAPY; CHEESE; DRUG ACTIVITY; DRUG MECHANISM; EOSINOPHILIA; FLUSHING; HEADACHE; HEMOLYSIS; HODGKIN DISEASE; HUMAN; HYPERSENSITIVITY; INFERTILITY; LEUKEMIA; LIVER DYSFUNCTION; LUNG INFILTRATE; PRIORITY JOURNAL; RASH; RED WINE; REVIEW; TREATMENT WITHDRAWAL;

EID: 4143092591     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2004.05.015     Document Type: Article

References (36)

1. Kenis Y., DeSmedt J., Tagnon H.J. Action du natulan dans 94 cas de tumeurs solides. Eur J Cancer. 2:1966;51-57
2. Alley M.C., Powis G., Appel P.L., et al. Activation and inactivation of cancer chemotherapeutic agents by rat hepatocytes co-cultured with human tumor cell lines. Cancer Res. 44:1984;549-556
3. Sinha B.K. Metabolic activation of PCB: evidence for carbon-centered free radical intermediates. Biochem. Pharmacol. 33:1984;2777-2781
4. Moloney S.J., Wiebkin P., Cummings S.W., Prough R.A. Metabolic activation of the terminal N-methyl group of N-isopropyl-alpha-(2 methylhydrazino)-p- toluamide hydrochloride (procarbbazine). Carcinogenesis. 6:1985;397-401
5. Prough R.A., Tweedie D.J. Procarcbazine. Powis G., Prough R.A. Metabolism and action of anticancer drugs. 1987;2-9 Taylor and Francis, London
6. Therman E. Chromosome breakage by 1-methyl-2-benzyl-hydrazine in mouse cancer cells. Cancer Res. 32:1972;1133-1136
7. Blijleven W.G., Vogel E. The mutational spectrum of PCB on drosophila melanogaster. Mutat. Res. 45:1977;47-59
8. Meer L., Schold S.C., Kleihues P. Inhibition of the hepatic O6-alkylguanine-DNA alkyltransferase in vivo by pretreatment with antineoplastic agents. Biochem. Pharmacol. 38:1989;929-934
9. Rossi S.C., Conrad M., Voigt J.M., et al. Excision repair of O6-methylguanine synthesised at the rat H-rasN-methyl-N-nitrosourea activation site and introduced in escherichia coli. Carcinogenesis (London). 10:1989;373-377
10. Hall J., Kataoka H., Sephenson C., et al. The contribution of O6-methylguanine and methylphosphotriesters to the cytotoxicity of alkylating agents in mammalian cells. Carcinogenesis (London). 9:1988;1587-1593
11. Schold S.C. Jr., Brent T.P., von Holfe E., et al. O6-alkylguanine-DNA alkyltransferase and sensitivity to PCB in human brain tumor xenografts. J. Neurosurg. 70:1989;573-577
12. Pegg A.E. Mammalian O6-alkylguanine-DNA alkyltransferase: regulation and importance in response to alkylating carcinogenic and therapeutic agents. Cancer Res. 50:1990;6119-6129
13. Friedman H.S., Jonhson S.P., Dong Q., et al. Methylator resistance mediated by mismatch repair deficiency in a glioblastoma multiforme xenograft. Cancer Res. 57:1997;2933-2936
14. Kat A., Thilly W.G., Fang W.H., et al. An alkylation-tolerant mutator human cell line is deficient in strand specific mismatch repair. Proc. Natl. Acad. Sci. USA. 90:1993;6424-6428
15. Koi M., Umar A., Chauhan D.P., et al. Human chromosome 3 corrects mismatch repair deficiency and microsatellite instability and reduces N-methyl-N'-nitro-N-nitrosoguanidine tolerance in colon tumor cells with homozygous hMLH1 mutation. Cancer Res. 54:1994;4308-4312
16. DeVita V.T., Serpick A.A., Carbonne P.P. Combination chemotherapy in the treatment of advanced Hodgkin's disease. Ann. Intern. Med. 73:1970;881-895
17. Schilsky R.L., Sherins R.J., Hubbard S.M., et al. Long-term follow up of ovarian function in women treated with MOPP chemotherapy for Hodgkin's disease. Am. J. Med. 71:1981;552-556
18. Horning S.J., Hoppe R.T., Kaplan H.S., et al. Female reproduction potential after treatment for Hodgkin's disease. N. Engl. J. Med. 304:1981;1377-1382
19. Grunwald H.W., Rosner F. Acute myeloid leukemia following treatment for Hodgkin's disease. Cancer. 50:1982;676-686
20. Tucker M.A., Coleman C.N., Cox R.S., et al. Risk of second cancers after treatment for Hodgkin's disease. N. Engl. J. Med. 318:1988;76-81
21. Sponzo R.W., Arseneau J., Canellos G.P. Procarbazine induced oxidative haemolysis: relationship to in vivo red cell survival. Br. J. Haematol. 27:1974;587-595
22. Dunagin W.G. Clinical toxicity of chemotherapeutic agents: dermatologic toxicity. Semin. Oncol. 9:1982;14-22
23. Garbes I.D., Henderson E.S., Gomez G.A., et al. PCB-induced interstitial pneumonitis with a normal chest X-ray: a case report. Med. Pediatr. Oncol. 14:1986;238-241
24. Mauch P.M., Armitage J.O., Diehl V., Hoppe R.T., Weiss L.M. Hodgkin's Disease. 1999;Williams & Wilkins, philadephia, Lippincott
25. Coltman C.A. Chemotherapy of advanced Hodgkin's disease. Semin. Oncol. 7:1980;155-173
26. Carde P., Mackintosh R., Rosenberg S.A. A dose and time response analysis of the treatment of Hodgkin's disease with MOPP therapy. J. Clin. Oncol. 1:1983;146-153
27. Travis L.B., Curtis R.E., Stovall M., et al. Risk of leukemia following treatment of non-Hodgkin's lymphoma. J. Nat. Cancer Inst. 86:1994;1450-1457
28. Yung L., Linch D. Hodgkin's lymphoma. Lancet. 361(9361):2003;943-951
29. Blayney D.W., Longo D.L., Young R.C., et al. Decreasing risk of leukemia with prolonged follow-up after chemotherapy and radiotherapy for Hodgkin's disease. N. Engl. J. Med. 316:1987;710-714
30. Andrea K.Ng., Patricia Bernardo M.V., Weller E., et al. second malignancy after Hodgkin disease treated with radiation therapy with or without chemotherapy: long-term risks and risk factors. Blood. 100(6):2002;1989-1996
31. Pazdur R., Coia L.R., Hoskins W.J., Wagman L.D. Cancer management: a multidisciplinary approach. 2003;The Oncology Group, New York
32. Santoro A., Bonfante V., Bonadonna G. Salvage chemotherapy with ABVD in MOPP-resistant Hodgkin's disease. Ann. Intern. Med. 96:1982;139-143
33. Canellos G.P., Anderson J.R., Propert K.J., et al. Chemotherapy of advanced Hodgkin's disease with MOPP,ABVD, MOPP alternating with ABVD. N. Engl. J. Med. 327:1992;1478-1484
34. Duggan D.B., Petroni G.R., Jojnson J.L., et al. Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an Intergroup trial. J. Clin. Oncol. 21:2003;607-614
35. Stanford V and radiotherapy for locally extensive and advanced Hodgkin's disease: mature results of a prospective clinical trial. J. Clin. Oncol 2002, 20, 630-37
36. Diehl V., Franklin J., Pfreundschuh M., et al. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N. Engl. J. Med. 348:2003;2386-2395